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Abstract
Background: Liver function tests (LFTs) are routinely performed in primary care, and are often the gateway to
further invasive and/or expensive investigations. Little is known of the consequences in people with an initial
abnormal liver function (ALF) test in primary care and with no obvious liver disease. Further investigations may be
dangerous for the patient and expensive for Health Services.
The aims of this study are to determine the natural history of abnormalities in LFTs before overt liver disease
presents in the population and identify those who require minimal further investigations with the potential for
reduction in NHS costs.
Methods/Design: A population-based retrospective cohort study will follow up all those who have had an incident
liver function test (LFT) in primary care to subsequent liver disease or mortality over a period of 15 years (approx.
2.3 million tests in 99,000 people). The study is set in Primary Care in the region of Tayside, Scotland (pop approx.
429,000) between 1989 and 2003. The target population consists of patients with no recorded clinical signs or
symptoms of liver disease and registered with a GP. The health technologies being assessed are LFTs, viral and auto-
antibody tests, ultrasound, CT, MRI and liver biopsy.
The study will utilise the Epidemiology of Liver Disease In Tayside (ELDIT) database to determine the outcomes of
liver disease. These are based on hospital admission data (Scottish Morbidity Record 1), dispensed medication
records, death certificates, and examination of medical records from Tayside hospitals. A sample of patients (n =
150) with recent initial ALF tests or invitation to biopsy will complete questionnaires to obtain quality of life data
and anxiety measures. Cost-effectiveness and cost utility Markov model analyses will be performed from health
service and patient perspectives using standard NHS costs. The findings will also be used to develop a computerised
clinical decision support tool.
Discussion: The results of this study will be widely disseminated to primary care, as well as G.I. hospital specialists
through publications and presentations at local and national meetings and the project website. This will facilitate
optimal decision-making both for the benefit of the patient and the National Health Service.
Published: 16 April 2007
BMC Health Services Research 2007, 7:54 doi:10.1186/1472-6963-7-54
Received: 6 March 2007
Accepted: 16 April 2007
This article is available from: http://www.biomedcentral.com/1472-6963/7/54
© 2007 Donnan et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Health Services Research 2007, 7:54 http://www.biomedcentral.com/1472-6963/7/54
Page 2 of 11
(page number not for citation purposes)
Background
Liver function tests (LFTs) are routinely performed in pri-
mary and secondary care, and are often the gateway to fur-
ther invasive and/or expensive investigations. Little is
known of the consequences in people with an initial
abnormal liver function (ALF) test [1]. Further investiga-
tions such as liver biopsy and endoscopic retrograde
cholangiopancreatography may be dangerous for the
patient and/or expensive for the National Health Service.
Recent guidelines for primary care have been published
for evaluation of abnormal liver enzyme results in asymp-
tomatic patients but did not cover other tests nor take
account of costs to the patient or the health service [2].
Despite the increasing use of LFTs, patients continue to
present with potentially fatal complications of undiag-
nosed end stage liver disease, which may have been pre-
ventable by earlier diagnosis. These include: autoimmune
hepatitis which is responsive to steroids, hepatitis C which
can be cured in a significant proportion of patients by
antiviral drugs, and alcohol misuse [3]. The abnormality
of liver function tests may be secondary to serious disease
elsewhere requiring treatment, such as malignancy where
its early detection may improve the prognosis. Improved
patient care demands integration of data from all stages of
the patient's illness in order to redesign services appropri-
ately [4,5]. There is a need for quality measures used in the
redesign process to be based on routinely collected data
rather than instituting specific record searches to address
current problems [6].
Most of the published epidemiological studies report only
the prevalence of liver disorders rather than addressing
the absolute or relative risks of subsequent liver injury fol-
lowing abnormal liver enzyme tests [7-9]. One study
examined incidence rates derived from selected hospital-
ised patients using data from mortality registries [10].
Duh et al, [11] quantified the incidence of liver enzyme
abnormalities in the general population but neglected
those subjects that subsequently retested normal or did
not retest at all, with no long term follow-up to possible
liver disease. Although the latter are minor and do not
indicate serious disease, they do utilise considerable
resources. Recently, a large cohort study in Korea (n = 142
055) reported the association between a key LFT serum
aminotransferase (AST and ALT) and mortality from liver
disease indicating that even values that were borderline
within the normal range were associated with poor out-
come [12,13].
Pilot work in Tayside demonstrated that approximately
25% of patients with ALF tests are dead within a year of
their first abnormal test result, although this includes
those with existing liver disease. A study from Nottingham
[14] has reported a similar prevalence of ALF tests and has
gone on to investigate the causes, intervening where inves-
tigation had not been performed or was inadequate.
Research objectives
a) To quantify and characterise incident abnormal liver
function (ALF) tests in the UK population using data from
Tayside and Nottingham. The subjects studied are those
with no clinically apparent liver disease with subsequent
maximum follow-up over a 15-year period of further
investigations, liver disease, non-liver disease and mortal-
ity. The study will determine those with no health conse-
quences, those who develop liver disease such as cirrhosis,
and its complications, or other liver diseases [see Addi-
tional file 1], as well as those who develop serious non-
hepatic illness such as cancer. In particular, to determine
outcomes at 2, 5 and 10 years and characterise those sub-
jects with:
1) ALF tests that upon investigation are judged as clini-
cally without liver disease;
2) ALF tests that upon investigation are diagnosed with
liver disease;
3) ALF tests with no further investigations and apparently
normal on follow-up;
4) ALF tests with no further investigations and diagnosed
with liver disease on follow-up;
Those who have an initially normal test may also have fur-
ther tests or no further tests and may or may not develop
liver disease. This important group enables estimation of
specificity and sensitivity of liver function tests.
b) To devise estimates of the probabilities of disease out-
comes following an ALF test with or without further inves-
tigations and determine what information would be most
useful to clinicians for predicting future patient outcomes
and guiding management.
c) To estimate and compare the costs to the National
Health Service in terms of LFTs, ultrasound, and other
investigative procedures and length of stay in hospital for
those with an initial ALF test or normal LFT.
d) To derive decision trees for the various pathways fol-
lowing ALF tests and estimate optimum management of
patients in primary care with cost-utility and cost-effec-
tiveness analyses.
Methods/Design
Design
A UK population-based observational cohort study will
follow up all those who have had an incident abnormalBMC Health Services Research 2007, 7:54 http://www.biomedcentral.com/1472-6963/7/54
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liver function test (ALF) as well as those who were initially
normal (to allow calculation of sensitivity, specificity) to
subsequent liver disease or mortality. Prior probabilities
will be based on pooled measures of prevalence of out-
comes in Tayside and Nottingham. Having obtained prior
probabilities and probabilities of outcomes from cohort
data using logistic or Cox regression modelling, these will
be used to create a decision analysis tree, which covers
clinically relevant pathways. Finally, the patient survey
will provide quality of life measures or utilities to enable
cost-utility and cost-effectiveness analyses to be carried
out.
Setting
The study is set within Primary Care in the region of Tay-
side, Scotland (pop ~. 429,000) between 1989 and 2003.
Additionally, primary care data with a median follow-up
of 15 months will be provided from Nottingham.
Target Population
Exclusions
Patients with no obvious clinical signs and symptoms of
liver disease with at least one liver function test and regis-
tered with a Tayside GP between 1989 and 2003 will be
eligible. A window of 6 months will be used to screen out
individuals with already existing liver disease and with
previous abnormal LFTs for monitoring purposes. This
will ensure only new incident tests in primary care will be
included on patients with no clinically obvious liver dis-
ease (figure 1).
The following exclusions will ensure that the study popu-
lation of patients have no clinically obvious liver disease
and only includes LFTs referred from primary care:
• Patients under 16
• Patients with liver disease or abnormal LFT in previous
6 months will be excluded
• Based on electronic biochemistry records we will
exclude patients whose initial LFTs are hospital referred
abnormal LFTs leaving all possible initially abnormal tests
requested from primary care
• We will exclude those who have a positive initial
bilirubin test (clearly jaundiced at presentation, bilirubin
> 35 µmol/l).
• Those with ascites, encephalopathy or variceal bleeding
within six weeks of their initial LFTs will be admitted to
hospital and can be identified from ELDIT database,
SMR1 record as well as spironolactone prescriptions from
the Health Informatics Centre database [15].
Health Technologies being assessed
LFTs antibody tests, ultrasound, CT, MRI and liver biopsy
[see Additional file 2]
Data Sources
The Epidemiology of Liver disease in Tayside (ELDIT) database
The ELDIT project created a liver database in Tayside link-
ing administrative clinical data with laboratory data [16].
Briefly, all electronic medical records (including labora-
tory tests) for Tayside were electronically linked with a
unique identifier, the community health index (CHI)
[15]. The community health index is used for all health
encounters in Tayside for the population registered with a
general practice. The following independent data sources
were electronically record linked, via the CHI, to maxim-
ise the accuracy of diagnosis and disease ascertainment:
• Prescribing database: The Health Informatics Centre
(HIC) has person-specific dispensing information for the
whole of Tayside [17],
• Hospitalisation, Scottish Morbidity Records (SMR1 –
general admissions, SMR4 – alcohol related psychiatric
admissions and SMR6 – cancer admissions),
• Death registry from the General Registry Office,
• Carstairs categories for social deprivation based on the
decennial census [18],
• Endoscopy,
• Regional biochemistry,
• Pathology,
• Virology, and
• Immunology databases.
Diagnostic algorithms for liver diseases have been created
and this database has already been used to assess the epi-
demiology and economic burden of viral hepatitis [19]
and other liver diseases.
The HIC prescription database is complete for all
encashed prescriptions for the Tayside population from
1989 to 2003. The hospitalisation records (SMR), and
mortality records are 100% complete for all admissions
for Tayside residents. There are likely to be gaps in the bio-
chemistry database as in the past, obscure databases were
used in some peripheral hospitals and could not be recov-
ered. However, this represents less than 1% of the total
data on liver function tests. Given that we will haveBMC Health Services Research 2007, 7:54 http://www.biomedcentral.com/1472-6963/7/54
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Selection of the study population of Liver function tests with no clinically obvious liver disease Figure 1
Selection of the study population of Liver function tests with no clinically obvious liver disease.
(n=853)
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approximately 2 million tests after exclusions, bias due to
missing tests will be minimal.
The ELDIT database as described above will provide
robust probabilities of outcomes. Costs of drugs, proce-
dures and hospital admissions will be obtained from
standard published values. We are currently updating the
ELDIT database to 2003, which is funded by the British
Liver Trust.
Prospective questionnaire data from patients undergoing
abnormal liver function tests as well as patients undergo-
ing liver biopsy will provide utility-based quality of life
measures in order to populate the decision trees. Permis-
sion will be sought from the general practitioner as well as
the patient. Other utility values will be obtained from the
literature and an expert panel of GPs and hepatologists.
Data from the Nottingham study with follow-up of
patients in primary care who received an ALF test with a
median follow-up of 15 months will also provide infor-
mation on indication, alcohol, BMI, height and weight.
Ethics and Data Protection
The proposal has Research Ethics Committee approval as
well as the Caldicott Guardians to ensure compliance with
the Data Protection Act. All data will be anonymised
according to the Standard Operating Procedures (SOPs)
of HIC so that the research will be conducted on non-
identifiable electronic data.
Proposed sample size
The annual incidence of ALF tests ranges from 489 to 869
per 100,000 people in the whole Tayside population
depending on type of test and year. With a total of approx-
imately 70,000 ALF tests over a 14 year period, of whom
approximately 5,500 have liver disease as defined by the
ELDIT database, power will be more than adequate (>
90%) to detect relative hazards of the order of 1.2 or
greater at the 5% significance level.
Statistical methods
Descriptive epidemiology for each group as defined by
pattern of ALF testing will include analysis of continuous
and categorical data on subject characteristics using χ2
tests for categorical variables and by t-tests for continuous
variables or non-parametric equivalents.
For the baseline population, liver function tests will be
extracted and number and frequency tabulated by year.
The 'liver function tests' will be:
Liver function
• Bilirubin
• Albumin
Liver damage
• Alkaline phosphatase (Alk Phos)
• Gamma-glutamyl transferase (GGT)
• Alanine transaminase (ALT)
• Aspartate aminotransferase (AST)(not routinely meas-
ured)
Normal and abnormal (and possibly mildly abnormal)
categories will be defined for each test using regional lab-
oratory standard cut-offs which vary by age and sex for
some tests (table 1). Sensitivity analyses will be performed
for some tests (eg ALT where mild abnormality or top
quartile in Normal range may be a useful category for pre-
diction.)
Categories of patterns of tests will be defined. For example
the following may be possible:
1. Raised ALT + normal Alk Phos + normal GGT (suggest-
ing hepatitis)
2. Raised Alk Phos +/- raised GGT + normal ALT (suggest-
ing biliary cirrhosis)
3. Any one abnormal
4. Any 2 or more abnormal and/or explore patterns.
Patterns of repeat tests will also be explored. The main
outcomes and covariates will be tabulated by initial and
repeat LFT patterns (Rates presented as events per thou-
sand person years).
Sensitivity, specificity, positive predictive value and likeli-
hood ratios will be calculated for LFT patterns compared
with actual outcome. Kaplan-Meier plots of time to out-
comes will be plotted for patterns of tests and individual
tests above.
Derivation of probabilities
Fixed 1, 2, 5 and 10-year probabilities of outcomes will be
estimated from logistic regression analyses. Probabilities
of outcome of liver disease or all cause mortality will be
calculated using the Cox proportional hazards regression
model [20] adjusting for confounders (such as age, sex,
co-morbidities, social deprivation), possibly incorporat-
ing time dependent covariates and between subject heter-
ogeneity using frailty terms [21]. As deriving probabilities
from the Cox model is not trivial, involving estimation ofBMC Health Services Research 2007, 7:54 http://www.biomedcentral.com/1472-6963/7/54
Page 6 of 11
(page number not for citation purposes)
the baseline hazard, an alternative is the Weibull paramet-
ric regression model which easily allows estimation of
probability of outcome over any time period. The Weibull
accelerated failure time model has been used to derive the
Framingham coronary heart disease (CHD) risk equation
[22] and a CHD risk score for type 2 diabetes from Tayside
data [23]. This gives greater flexibility in modelling over
different time periods.
The main outcomes will be all-cause mortality (Yes/No);
Liver disease mortality (Yes/No); Liver disease such as
non-alcoholic fatty liver disease (NAFLD), alcohol related
liver disease, viral hepatitis and primary biliary cirrhosis
(PBC) (Yes/No); Any hospitalization; Cirrhosis/portal
Hypertension.
The above models will also allow derivation of risks of
outcomes stratified by factors entered in the regression
model. For example, the risk of liver disease is clearly
greater in patients with known alcohol abuse compared to
those without alcohol abuse. The following factors will be
entered in the regression models to assess their effect on
risk and estimate factor-specific risks:
1) Further tests such as repeated LFTs, liver biopsy, ultra-
sound, virology, immunology and ferritin as well as time
between tests. Other baseline stratification factors may be:
2) Age – derived from the first 6 digits of patient identifier,
the community health index (may be categorized as < 40
and 40+ depending on age distribution);
3) Gender – derived from the 9th digit of the patient iden-
tifier, the community health index;
4) Pregnancy – from hospitalisation records, SMR2. This
will, of course, miss home births;
5) Opioid abuse – A proxy measure will be obtained using
methadone prescribing from the HIC prescription data-
base
6) Alcohol abuse – We will use hospitalisation records
from SMR1 and SMR6 which includes ICD10 codes F10,
X65 and T51. Y90 and Y91 may be used as supplementary
information. This will represent the more extreme end of
alcohol abuse which is a weakness in missing others with
Table 1: Liver function tests and definitions of abnormal
Liver Function test Range Normal (Age & Gender) Moderately abnormal Severely abnormal
Bilirubin (µmol/l) 0–1000 <18 M
<16 F
18 – 42.5 M
16 – 37.5 F
>42.5 M
>37.5 F
Albumin (g/l) 11–60 >35 30–35 <30
Alk Phos (IU/l) 20–2000 120–455 M 16–19 455–1138 >1138
45 – 195 M 19–26 195–488 >488
30 – 105 M 26–55 105–263 >263
45 – 130 M 56–75 130–325 >325
65 – 150 M 75+ 150–375 >375
120–420 F 16–19 420–1050 >1050
25 – 90 F 19–26 90–225 >225
20 – 80 F 26–55 80–200 >200
40 – 150 F 56–75 150–375 >375
50 – 190 F 75+ 190–475 >475
GGT (IU/l) 5–2000 7 – 42 All 16–24 42–105 >105
9 – 70 M 24–34 70–175 >175
11– 75 M 34–44 75–188 >188
11 – 82 M 44–55 82–205 >205
11 – 70 M 55+ 70–175 >175
5 – 35 F 24–34 35–88 >88
5 – 42 F 34–44 42–105 >105
5 – 65 F 44–55 65–163 >163
5 – 75 F 55+ 75–188 >188
ALT (IU/l) 12–9999 depending on age 
and sex
14 – 40 M 16–18 40–100 >100
15 – 55 M 18–55 55–138 >138
12 – 35 F 16–18 35–88 >88
12 – 40 F 18–55 40–100 >100
13 – 43 All 55–75 43–108 >108
6 – 30 All 75+ 30–75 >75
AST (IU/l) 3 – 30 M 17–65 30 – 75 >75
10 – 45 F 16–75 45 – 113 >113
10 – 30 75+ 30 – 75 >75BMC Health Services Research 2007, 7:54 http://www.biomedcentral.com/1472-6963/7/54
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mild or moderate alcohol abuse. On the other hand, this
is also a strength in giving a clear definition and measures
of the drivers of costs to the health service. The alternative
of general practice notes would be prohibitively expensive
and prone to classification error.
7) Social deprivation – The Carstairs social deprivation
score assigned to postcodes for all residents of Tayside, is
derived from the decennial census, incorporating the var-
iables, housing density, car ownership, social class of the
head of household and male unemployment [18].
Although social deprivation is a marker for cigarette
smoking and co-morbidity, we will also be able to assess
the affect of individual co-morbidities on risk.
8) Diabetes will be defined from the Diabetes Audit and
Research in Tayside, Scotland (DARTS) database which is
97% sensitive for ascertainment of diabetes in the popu-
lation [23].
9) The Hearts database (sensitivity 95%) will identify
those who have definite CHD (myocardial infarction or
demonstrated coronary artery disease) in the Tayside pop-
ulation [24].
Other major co-morbidities [see Additional file 3] such as
10) respiratory disease
11) cerebrovascular disease,
12) renal disease,
13) ischaemic heart disease,
14) cancers other than liver cancer
will be defined by the Scottish Morbidity Record which
contains details of all hospital admissions, including
ICD9, ICD10 codes, for all Tayside residents, which is
held in HIC.
HIC also contains the database of all encashed prescrip-
tions in Tayside. This resource can also be used to create
co-morbidity variables such as
15) Psychotropic drugs: monoamine oxidase inhibitors,
Phenothiazines
16) Analgesics: NSAIDS, paracetamol, aspirin
17) Antibiotics
18) Lipid lowering agents such as statins and fibrates
19) sodium valproate
20) oestrogens (oral contraceptives, HRT)
Importantly, this resource will allow us to identify receipt
of prescribed hepatotoxic drugs at the time of any ALF test.
Costs which are invariably positively skewed will be sum-
marised and compared between cohorts using bootstrap-
ping procedures for means and confidence intervals
[26,27]. Statistical analysis will be performed on SAS ver-
sion 8.0 (SAS Institute, Cary, NC)
Decision analyses
Decision analysis is the formal process whereby the prob-
abilities of outcome events, such as liver disease, are com-
bined with patients' preferences or values. The approach is
most useful in informing clinical decisions where the
optimal pathway is not immediately apparent, and for
making clinical reasoning explicit [28]. Hence, these anal-
yses will inform the management of patients with an
abnormal liver function test, but who are otherwise well.
The probabilities of outcomes are generally derived from
regression analysis of cohort studies of large populations
or from previous published results. The analysis of the
Tayside population will provide robust estimates of these
probabilities stratified by important confounders. For
example, the measurement of alkaline phosphatase is
known to be dependent on age, gender, and blood type
and so the probability estimate needs to be adjusted
appropriately. The Weibull regression analyses described
above can be enhanced using a Bayesian approach
whereby prior probabilities (prevalence or previous pub-
lished results) can be updated by new data, utilizing the
software WinBUGS.
Utilities can be extracted from previously published work
but it is likely this form of research is sparse in liver dis-
ease. A utility of 1 is taken to represent optimal health,
while 0 represents death. Utilities are combined with
length of time in a condition or state to give quality
adjusted life years (QALYs), where QALY = QOL multi-
plied by length of time in the state. For example, a com-
monly quoted utility for stroke is 0.75, meaning that 4
years suffering from stroke has a QALY = 3 years. Alterna-
tives to published results include panels of liver disease
experts constructing values that appear to have face value.
Ideally, utilities can be obtained directly from patients
using QOL utility measures such as EQ-5D. This instru-
ment is easily used in questionnaires and has 5 dimen-
sions, each with three levels generating 243 theoretically
possible health states covering mobility, self-care, usual
activities, pain/discomfort, anxiety/depression. The pro-
spective questionnaire for patients undergoing a liver
function test and patients undergoing liver biopsy willBMC Health Services Research 2007, 7:54 http://www.biomedcentral.com/1472-6963/7/54
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provide utility data essential for the cost-utility analysis in
which the decision analysis aims to maximize expected
utility. This questionnaire survey will focus on the more
serious investigations such as liver biopsy, as the utility of
a single liver function test such as bilirubin in an other-
wise healthy patient is likely to be close to 1. A literature
search will enable us to find and possibly pool estimates
of liver diseases such as hepatitis C and various stages of
cirrhosis.
Decision analyses also allow other measures such as costs
to be incorporated and the analysis aims to minimize
costs or maximize cost-effectiveness from a health service
perspective. An example of how a decision tree for alka-
line phosphatase might look is given in figure 2. This has
been simplified for presentation, and is based on Pratt
and Kaplan [2]
One limitation of decision analysis is that the time hori-
zon is generally short and costs, utilities and probabilities
may vary over time as well as by type of liver disease.
However, the approach of Markov modeling allows exten-
sion of time indefinitely and hence is useful for modelling
cost and utilities until death of all members of the cohort
[29]. The Markov process simulates movement of an indi-
vidual or cohort through various states, each of which is
associated with a probability, utility and cost. As some
liver disease may not be apparent in a short period of time
Markov modelling will be utilized in modelling cost-effec-
tiveness and cost-utility analysis over longer time periods.
As the probabilities, cost and utilities are fixed estimated
values in decision analysis, it is more realistic to allow for
error of these measures using Bayesian methods in proba-
bilistic sensitivity analyses. Decision analyses will utilize
the software Data 4 (TreeAge).
Proposed outcome measures
The study will use the epidemiology of liver disease data-
base (ELDIT) in Tayside, and the Nottingham cohort to
determine the outcome of liver disease (as listed in appen-
dix 2). In Tayside, outcomes of the extent of liver disease
and co-morbidities of subjects with no retest or subse-
quent normal liver function tests will be determined by
hospital admission data (Scottish Morbidity Record 1),
dispensed medication records, death certificates, and
examination of medical records from Tayside hospitals.
Those with normal tests are less likely to be investigated
and hence classified with liver disease on death certifi-
cates. Simulation of likely misclassification rates will
demonstrate whether this potential bias has a large influ-
ence on results. Sensitivity, specificity, positive and nega-
tive likelihood ratio and yield (1/PPV) will be calculated
for each pathway. All liver function tests (LFTs) will be
obtained from the ELDIT and biochemistry databases and
standard costs applied. All procedures and hospitalisa-
tions of all subjects will be obtained from the Tayside por-
tion of the SMR1 record and the cost per day by speciality
and hospital will be applied from published NHS costs.
Future costs will be discounted at 6% per year, where nec-
essary.
Cost-effectiveness and cost utility analyses will be per-
formed from health service and patient perspectives. Cost
effectiveness will seek to minimise the cost of investiga-
tions per case of liver disease detected, while cost-utility
analyses will seek to maximize expected utility. In the
Markov models effectiveness is measured as life expect-
ancy by risk factor strata, adjusted using utilities to give
QALYs.
The findings will also be used to develop a computerised
clinical decision support tool. This will be evaluated and
validated in a further study as the subject of a separate
application as part of a program of research in Dundee's
Health Informatics Centre (HIC), where funded develop-
ment of decision support tools in cardiovascular risk, cae-
sarean delivery, breast and colorectal cancer are already
underway. The results of this study will be widely dissem-
inated to primary care, as well as G.I. hospital specialists
through publications and presentations at local and
national meetings and the project website This will facili-
tate optimal decision-making both for the benefit of the
patient and the National Health Service.
Discussion
Consumers
The Health Informatics Centre has developed a User Par-
ticipation Group for input from the consumer for research
ideas, development of research tools, and dissemination.
The views of this group will be sought in developing the
study materials in relation to the patient survey and in dis-
semination of the results.
Impact on and benefit to the NHS
Abnormal liver enzymes may indicate liver injury which is
asymptomatic in the early stages and subsequent testing
may diagnose symptomatic liver disease. The probability
of disease is unknown. The sequence of subsequent tests
is at the discretion of the practitioner. The care pathway
will give clinical sequencing for subsequent testing and
follow-up, thus maximising the probability of diagnosis
and eliminating unnecessary expense to the NHS and
unwanted patient trauma. The decision support system
developed could be used in conjunction with the elec-
tronic results communications system within Tayside,
which could be subsequently rolled out across the NHS.
Tayside is a lead site for Scotland's Electronic Clinical
Communications Initiative that has the philosophy of a
single clinical web-based repository linked to the locallyBMC Health Services Research 2007, 7:54 http://www.biomedcentral.com/1472-6963/7/54
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developed Area Community Health Index. The Tayside
Core Network connects every GP practice and hospital
within Tayside with a single access to NHSNet and pres-
ently has 88 sites with over 4000 PCs connected. This pro-
posal will be developed, within the IT framework
established by the Board and the Trusts to ensure that the
decision support system, this project develops can be ade-
quately supported by them and demonstrate the practical-
ity for the wider NHS.
In summary, this study will determine the natural history
of abnormalities in LFTs before overt liver disease presents
in the population and will also provide identification of
those who require minimal further investigations with the
potential for reduction in NHS costs.
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Example of possible simplified decision analysis tree following alkaline phosphatase test (LD – liver disease, based on Pratt and  Kaplan, 2000) Figure 2
Example of possible simplified decision analysis tree following alkaline phosphatase test (LD – liver disease, based on Pratt and 
Kaplan, 2000).
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SMR – Scottish Morbidity Record
CHI – Community Health Index
QALY – Quality Adjusted Life Year
ALT – Alanine transaminase
GGT – Gamma-glutamyl transferase
AST – Aspartate aminotransferase
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